Skip to the page

Data / Form D filings / Firefly Bio, Inc.

Firefly Bio, Inc.: Form D filing

Firefly Bio, Inc., a biotechnology company in South San Francisco, CA, filed a Form D with the SEC in 2024. The latest, on March 26, 2024, reports $40 million sold of a $72 million offering to 8 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
2 TOWER PLACE UNIT 14A, South San Francisco, CA, 94080
Phone
(650) 442-2025
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2022
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2006498

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Mar 26, 2024New notice$72,000,000$39,999,997$32,000,0038Dec 18, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
John FlygareExecutive Officer
Jerel DavisDirector
Pankaj BhargavaDirector
Todd FoleyDirector
Bernhard GeierstangerExecutive Officer
Alexander MaywegDirector
Peter ColabuonoDirector
Scott HirschExecutive Officer, Director

Other biotechnology companies in California that filed recently

Every Form D from the week of Mar 25, 2024 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Firefly Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.